Makoto Takeuchi

Mr. Takeuchi previously spent 35 years at Yamanouchi Pharmaceutical Co., Ltd. and Astellas Pharma Inc. in roles of increasing responsibility in the Research Division and ultimately up to Senior Corporate Executive and Head of External Relations. He has extensive experience in industrial pharmaceutical research, especially in gastrointestinal diseases, inflammation, bone metabolism, infection, and the oncology areas, and he was deeply involved in the discovery and launch of new medicines such as Incadronate, Minodronate and Solifenacin for the treatment of hypercalcemia, osteoporosis and overactive bladder, respectively. He also studied abroad at the University of Pennsylvania (Prof. Amos Smith III) for one year from 2001.

In July 2018, he joined FTI.

He has also worked for the Japan Pharmaceutical Manufacturers Association (JPMA) as chairman of the Pharmaceutical Industrial Policy Committee and R & D Committee, for the Drug Discovery Support Network as a member of the advisory board, the National Institute of Advanced Industrial Science and Technology (AIST) as a member of the verification committee of AIST self-evaluation, and the Forum for Innovative Regenerative Medicine (FIRM) as a vice chairman and so on.

He has also served as a part-time lecturer in the Faculty of Pharmaceutical Sciences (2009-15) and Forefront of Drug Discovery (FDD) Seminar (2011-present), at the University of Tokyo and at the Faculty of Pharmacy and Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University (2010-2012).

He graduated from the Graduate School of Medicine and Pharmaceutical Science, Toyama Medical and Pharmaceutical University.